Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2018, Article ID 4543065, 8 pages
https://doi.org/10.1155/2018/4543065
Research Article

Fibrin Clot Strength in Patients with Diabetes Mellitus Measured by Thrombelastography

Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN, USA

Correspondence should be addressed to Rolf P. Kreutz; ude.ui@ztuerkr

Received 13 September 2017; Accepted 30 November 2017; Published 4 February 2018

Academic Editor: Giovanni de Gaetano

Copyright © 2018 Benjamin T. Maatman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. B. Kannel and D. L. McGee, “Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study,” Diabetes Care, vol. 2, no. 2, pp. 120–126, 1979. View at Publisher · View at Google Scholar
  2. K. Pyörälä, M. Laakso, and M. Uusitupa, “Diabetes and atherosclerosis: an epidemiologic view,” Diabetes/Metabolism Research and Reviews, vol. 3, no. 2, pp. 463–524, 1987. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Stamler, O. Vaccaro, J. D. Neaton, D. Wentworth, and The Multiple Risk Factor Intervention Trial Research Group, “Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial,” Diabetes Care, vol. 16, no. 2, pp. 434–444, 1993. View at Publisher · View at Google Scholar
  4. S. M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–243, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Barrett-Connor, “Diabetes and heart disease,” Diabetes Care, vol. 26, no. 10, pp. 2947–2958, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Petursson, J. Herlitz, K. Caidahl et al., “Admission glycaemia and outcome after acute coronary syndrome,” International Journal of Cardiology, vol. 116, no. 3, pp. 315–320, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Rabini, R. Staffolani, P. Fumelli, B. Mutus, G. Curatola, and L. Mazzanti, “Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients,” Diabetologia, vol. 41, no. 1, pp. 101–104, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Davì, I. Catalano, M. Averna et al., “Thromboxane biosynthesis and platelet function in type II diabetes mellitus,” The New England Journal of Medicine, vol. 322, no. 25, pp. 1769–1774, 1990. View at Publisher · View at Google Scholar
  9. Y. Zhu, P. Carmeliet, and W. P. Fay, “Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance,” Circulation, vol. 99, no. 23, pp. 3050–3055, 1999. View at Publisher · View at Google Scholar
  10. R. P. Kreutz, P. Nystrom, Y. Kreutz et al., “Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin,” Platelets, vol. 24, no. 2, pp. 145–150, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. W. B. Kannel, R. B. D'Agostino, P. W. F. Wilson, A. J. Belanger, and D. R. Gagnon, “Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience,” American Heart Journal, vol. 120, no. 3, pp. 672–676, 1990. View at Publisher · View at Google Scholar · View at Scopus
  12. M. T. Ganter and C. K. Hofer, “Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices,” Anesthesia & Analgesia, vol. 106, no. 5, pp. 1366–1375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Bitar and R. P. Kreutz, “Role of thrombelastography (TEG) in risk assessment and guidance of antithrombotic therapy in patients with coronary artery disease,” Drug Development Research, vol. 74, no. 8, pp. 533–540, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Lu, J. Owens, and R. P. Kreutz, “Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes,” Thrombosis Research, vol. 132, no. 2, pp. e94–e98, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. R. P. Kreutz, J. Owens, J. A. Breall et al., “C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting,” Blood Coagulation & Fibrinolysis, vol. 24, no. 3, pp. 321–326, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. P. A. Gurbel, K. P. Bliden, K. Guyer et al., “Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1820–1826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. R. P. Kreutz, G. Schmeisser, B. Maatman et al., “Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention,” Thrombosis and Haemostasis, vol. 117, no. 2, pp. 426–428, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. R. P. Kreutz, A. Bitar, J. Owens et al., “Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease,” Journal of Thrombosis and Thrombolysis, vol. 38, no. 3, pp. 380–387, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, no. 4, article e57, 2010. View at Google Scholar
  20. O. N. Okafor and D. A. Gorog, “Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk,” Journal of the American College of Cardiology, vol. 65, no. 16, pp. 1683–1699, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. E. I. Lev, K. P. Bliden, Y. H. Jeong et al., “Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients,” Journal of the American Heart Association, vol. 3, no. 5, article e001167, 2014. View at Publisher · View at Google Scholar
  22. V. G. Nielsen, W. Q. Gurley Jr, and T. M. Burch, “The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography,” Anesthesia & Analgesia, vol. 99, no. 1, pp. 120–123, 2004. View at Publisher · View at Google Scholar
  23. G. Di Giovine, M. Verdoia, L. Barbieri et al., “Impact of diabetes on fibrinogen levels and its relationship with platelet reactivity and coronary artery disease: a single-centre study,” Diabetes Research and Clinical Practice, vol. 109, no. 3, pp. 541–550, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. B. A. Lemkes, J. Hermanides, J. H. Devries, F. Holleman, J. C. Meijers, and J. B. Hoekstra, “Hyperglycemia: a prothrombotic factor?” Journal of Thrombosis and Haemostasis, vol. 8, no. 8, pp. 1663–1669, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. P. J. Grant, “Diabetes mellitus as a prothrombotic condition,” Journal of Internal Medicine, vol. 262, no. 2, pp. 157–172, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. J. Price, D. J. Angiolillo, P. S. Teirstein et al., “Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial,” Circulation, vol. 124, no. 10, pp. 1132–1137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. M. E. Carr, “Diabetes mellitus: a hypercoagulable state,” Journal of Diabetes and its Complications, vol. 15, no. 1, pp. 44–54, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. J. H. Jung, U. S. Tantry, P. A. Gurbel, and Y. H. Jeong, “Current antiplatelet treatment strategy in patients with diabetes mellitus,” Diabetes & Metabolism Journal, vol. 39, no. 2, pp. 95–113, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Cersosimo and R. A. DeFronzo, “Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases,” Diabetes/Metabolism Research and Reviews, vol. 22, no. 6, pp. 423–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. V. R. Vaidyula, A. K. Rao, M. Mozzoli, C. Homko, P. Cheung, and G. Boden, “Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand,” Diabetes, vol. 55, no. 55, p. 1, 2006. View at Publisher · View at Google Scholar
  31. J. W. Eikelboom, S. J. Connolly, J. Bosch et al., “Rivaroxaban with or without aspirin in stable cardiovascular disease,” The New England Journal of Medicine, vol. 377, no. 14, pp. 1319–1330, 2017. View at Publisher · View at Google Scholar